ArticleJournal of gastrointestinal oncology2020
Discovery of a novel three-long non-coding RNA signature for predicting the prognosis of patients with gastric cancer.
Article in Journal of gastrointestinal oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Identification of a G-quadruplex-forming cell-free DNA fragment as a biomarker for the precise diagnosis of hepatocellular carcinoma.Chemical science · 2026Article
- A Bioinformatics-Driven ceRNA Network in Stomach Adenocarcinoma: Identification of Novel Prognostic mRNA-miRNA-lncRNA Interactions.Medical sciences (Basel, Switzerland) · 2025Article
- Development and experimental validation of a senescence-related long non-coding RNA signature for prognostic prediction and immune microenvironment characterization in gastric cancer patients.Journal of gastrointestinal oncology · 2024Article
- Development and validation of a two glycolysis-related LncRNAs prognostic signature for glioma and in vitro analyses.Cell division · 2023Article
- Construction of a prognostic glycolysis-related lncRNA signature for patients with colorectal cancer.Cancer medicine · 2023Article
- Identification of prognostic alternative splicing signature in gastric cancer.Archives of public health = Archives belges de sante publique · 2022Article
- Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Construction and validation of a glycolysis-related lncRNA signature for prognosis prediction in Stomach Adenocarcinoma.Frontiers in genetics · 2022Article
- Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer.Annals of translational medicine · 2021Article
- Development of an Immune-Related LncRNA Prognostic Signature for Glioma.Frontiers in genetics · 2021Article
- Survival-Related lncRNA Landscape Analysis IdentifiesFrontiers in genetics · 2021Article
- A novel 8-genome instability-associated lncRNAs signature predicting prognosis and drug sensitivity in gastric cancer.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence demonstrates that long non-coding RNAs (lncRNAs) play a predictive role in the prognosis of gastric cancer (GC). The present study aims to construct a lncRNA-based model via mining data of The Cancer Genome Atlas (TCGA).
methodsDifferentially expressed lncRNAs were first identified, followed by univariate Cox analysis, Robust likelihood-based survival model and multivariate Cox analysis to construct a signature composed of lncRNAs.
resultsA three-lncRNA based predictive signature (OVAAL, FLJ16779, FAM230D) was established to stratify GC patients into high- and low-risk groups. Patients in the high-risk group had markedly shorter overall survival (OS) than those in the low-risk group, which was verified by the ROC curve. Then, we validated the predictive power of the scoring system in other two cohorts. Multivariate Cox analysis also indicated that the 3-lncRNA signature was an independent prognostic factor for survival prediction in GC patients. Moreover, Gene Set Enrichment Analysis (GSEA) revealed that diverse metabolic pathways significantly clustered in the low-risk group, which might explain how the 3-lncRNA signature promoted gastric carcinogenesis.
conclusionsWe established a robust three-lncRNA model to predict the OS of GC patients, which might benefit the clinical decision making for personalized treatment and prognostic prediction for GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.